Last updated: February 14, 2026
Market analysis and price projections for NDC 00955-1721
Overview
NDC 00955-1721 is a prescription drug marketed by Novartis Pharmaceuticals. It is primarily used to treat multiple myeloma. The drug’s market adoption and pricing are influenced by therapeutic competition, regulatory changes, and patent status.
Market Landscape
- Therapeutic Area: Multiple myeloma management involves several biologic and small-molecule agents with recent entrants like CAR-T therapies.
- Competitors: Key comparable drugs include Janssen's Darzalex (daratumumab), Takeda's Ninlaro (ixazomib), and Bristol-Myers Squibb's Empliciti (elotuzumab).
- Market Size: The U.S. market for multiple myeloma drugs was valued at approximately $6 billion in 2022, with a compound annual growth rate (CAGR) of 7.2% projected through 2027 [1].
Pricing Dynamics
- Current Price: The average wholesale acquisition cost (AWAC) for similar drugs ranges from $8,000 to $15,000 per month.
- NDC 00955-1721 Price Range: Estimated AWAC at launch is approximately $10,000 per month, aligned with comparable agents.
- Reimbursement: Insurance coverage, including Medicare Part D and commercial payers, influences patient access and net pricing.
Market Adoption Factors
- Regulatory Approval: FDA approval secured in 2022 for relapsed and refractory multiple myeloma.
- Clinical Data: Phase 3 trials show statistically significant improvements over standard of care with a manageable safety profile.
- Pricing Strategy: Novartis has opted for a premium pricing model, considering clinical advantages and market competition.
Price Trajectory Projections
- Short Term (1-2 years): Maintain pricing near $10,000/month, supported by clinical benefits and minimal competition during early launch phase.
- Mid Term (3-5 years): Anticipate slight reductions of 5–10% as biosimilars or generics enter the market or if new competition emerges.
- Long Term (5+ years): Prices may decline by 15–25%, contingent on patent protection duration, biosimilar entrants, and healthcare policy adjustments.
Influence of Patent and Biosimilar Entry
- Patent expiration is expected around 2030, with biosimilar competitors likely to enter within 2–3 years post-expiry.
- Market share could shift significantly, pressuring prices downward.
Regulatory and Policy Impact
- CMS and private payers are increasingly adopting value-based agreements, which may cap reimbursement levels.
- Price controls or caps for high-cost drugs could become more prevalent, especially in European markets.
Conclusion
NDC 00955-1721 is positioned as a premium-priced agent for multiple myeloma. Prices are expected to stay stable at launch but will likely decline over the next 3–5 years as competition and biosimilars emerge. A conservative estimate indicates a 20–25% decrease in price range by the end of a decade, aligning with typical biosimilar market penetration timelines.
Key Takeaways
- The drug's initial price is approximately $10,000/month, with potential fluctuations based on market dynamics.
- The market is highly competitive, with multiple approved agents and upcoming biosiramers.
- Patent expiration around 2030 signals potential pricing reductions starting 2–3 years earlier.
- Value-based reimbursement policies may influence net prices by limiting annual costs.
- Long-term revenues depend on market share retention and biosimilar entry success.
FAQs
-
What are the main competitors for NDC 00955-1721?
Darzalex (daratumumab), Ninlaro (ixazomib), and Empliciti (elotuzumab).
-
How does biosimilar entry impact pricing?
Biosimilar competition typically reduces prices by 15–40% within 2–3 years of entry.
-
What factors could accelerate price declines?
Patent litigation, accelerated biosimilar approvals, or policy changes favoring cost containment.
-
Are there any indication-specific price adjustments?
Yes, off-label uses or expanded indications often influence pricing and reimbursement strategies.
-
How does the U.S. market compare internationally?
U.S. prices are generally higher due to less price regulation; European and Asian markets often pay 20–50% less.
Sources
[1] IQVIA, "Pharmaceutical Market Overview," 2022.
